Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Suhail M Hadi
The Mount Sinai Medical Center, USA
Posters & Accepted Abstracts: J Clin Exp Dermatol Res
221 patches of stable vitiligo from 97 patients of different ethnic backgrounds were treated with this modality of treatment. 54 were males and 43 were females. Mean age was 33.5 years. 30 lesions were left untreated as controls. Patients were treated for 30 sessions or 75% re-pigmentation or more, whichever comes first. Initial dose was 100 mj/cm2 which is increased by 1/2 MED (50 mj/cm2) until erythema developed. Treatment was given twice per week. 50.6% of treated lesions showed 75% re-pigmentation or more. 64.3% of lesions showed 50% re-pigmentation or more. Lesions on the face showed the best response with 77.6% of them achieved 75% repigmentation or more and 81.3% had 50% re-pigmentation or more. Patients with skin phototype III-VI had the best results. None of the control patches developed pigmentation. No significant side effects were encountered and none of the responding patients lost their pigment during the two year follow up.
Email: smhadi@dr.com